FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Oxular

News
Article

Oxular has been granted rare pediatric disease and orphan drug designations by the US FDA for its proprietary drug, OXU-003.

According to an Oct. 12, 2020 press release, Oxular, a retinal therapeutics development company, has been granted rare pediatric disease and orphan drug designations by the US Food and Drug Administration (FDA) for its proprietary drug, OXU-003.

OXU-003 is currently under development for the treatment of retinoblastoma, a form of eye cancer that usually develops in early childhood. Current treatment options for retinoblastoma are invasive and require specialized facilities. OXU-003 consists of a proprietary anti-tumor drug that uses Oxular’s formulation and ocular administration technology to deliver a precise amount of drug adjacent to the primary ocular tumor.

“I am very pleased to see the US FDA’s acknowledgement of the critical and urgent need to develop an effective, safer, and easily accessible treatment for retinoblastoma, which is such a devastating disease,” said Manoj Parulekar, pediatric consultant ophthalmologist, Birmingham (UK) Children’s Hospital, in the press release. “Given the potential severe side effects associated with current treatments, which can have life-long impact on children’s lives, it is important that these patients have another treatment available to them.”

“We are delighted to receive these rare pediatric disease and orphan drug designations, which provide important momentum for our OXU-003 development program, as we expect to enter human clinical trials and generate data within the next two years,” added Thomas Cavanagh, CEO of Oxular, in the press release. “OXU-003 is a potential breakthrough therapy that utilizes Oxular’s core technology to maximize the opportunity for successful treatment while preserving quality of life for these young patients.”

Source: Oxular

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes